Authors

Carrie L. Kitko, MD is an associate professor of pediatrics, Hematology/Oncology, Ingram Professorship in Pediatric Oncology, in the Department of Pediatrics, and the medical director of the Pediatric Stem Cell Transplantation Program at Vanderbilt University Medical Center, part of Vanderbilt Children's Hospital.

Latest:

Dr Kitko on Clinical Outcomes With Axatilimab According to Prior Lines of Therapy for Chronic GVHD

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.

Sushmita Gordhandas, MD

Latest:

Ovarian Cancer Prevention With the Opportunistic Salpingectomy: An Opportunity for Multidisciplinary Collaboration

A new understanding of pathogenesis has given rise to a promising prevention strategy for women at an average risk of developing ovarian cancer through surgical removal of the fallopian tubes, referred to as an opportunistic salpingectomy.

Dionisia Quiroga, DO, PhD

Dionisia Quiroga, DO, PhD, is a breast medical oncologist and assistant professor in the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center

Latest:

Dr Quiroga Shares Breast Cancer Insights

Dionisia Quiroga, DO, PhD, discusses breast cancer insights.

Seth Wander, MD, PhD

Latest:

Patient-Reported Outcomes From the SERENA-6 Trial of Camizestrant + CDK4/6 Inhibitor For Emergent ESR1m During First-Line Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer

Seth Wander, MD, PhD discusses an overview of emerging data and evolving treatment strategies in advanced gastric and gastroesophageal cancers, with a focus on the role of biomarkers in guiding targeted and immunotherapy-based treatment. The presentation highlights clinical trial outcomes, testing considerations, and future directions shaping the personalized management of these patients.

Shuo Ma, MD, PhD

Latest:

Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

Bradley Monk, MD

Latest:

Unmet Needs and Future Research Focus for Endometrial Cancer

Panelists discuss how addressing molecular, clinical, and access-related gaps remains essential for advancing endometrial cancer research and care.

Yiming Wu, PhD

Latest:

Dr Wu on the Role of METTL3-Mediated m6A Modification in CLL Progression

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

Vadim S. Koshkin, MD

Vadim Koshkin, MD, is an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine, as well as a genitourinary medical oncologist at the UCSF Helen Diller Comprehensive Cancer Center

Latest:

Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

Drs Park and Koshkin explore the clinical implications of the phase 3 NIAGARA trial for patients with resectable bladder cancer.

Pamela J. Sung, MD, PhD

Latest:

Differentiation Therapy in Acute Myeloid Leukemia: Not Just for APL Anymore

Pamela J Sung, MD, PhD, details differentiation therapy in acute myeloid leukemia, focusing on newer targets and preclinical evidence for a novel FLT3 combination.

Mitchell Parma, MD

Mitchell Parma, MD, a clinical fellow in Hematology/Oncology at the University of Texas MD Anderson Cancer Center

Latest:

Dr Parma on Survival Outcomes With Immunotherapy in Patients With NSCLC Brain Metastases

Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.

Edward Kim, MD, Mount Sinai Medical Center

Latest:

Dr. Kim on the Future Role of Y-90 in Patients with Unresectable HCC

Edward Kim, MD, discusses the future role of Y-90 in patients with unresectable hepatocellular carcinoma.

Emily S. Ruiz, MD, MPH, FAAD

Michael Dennis, MD

Michael Dennis, MD, is a physician at Dana-Farber Cancer Institute; as well as an instructor in medicine at Harvard Medical School

Latest:

Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD

Dr Dennis discusses guidelines for nasopharyngeal carcinoma management and data with first-line toripalimab plus chemotherapy in metastatic disease.

Bridget Hoyt

Latest:

Oral and Subcutaneous Azacitidine Show Comparable PK, Safety Profiles in MDS and CMML

Oral azacitidine demonstrated a similar pharmacokinetic and safety profile to the subcutaneous formulation in MDS or CMML.

Keiichi Fujiwara, MD, PhD

Latest:

Dr Fujiwara on the FDA Approval of Tisotumab Vedotin for Recurrent Cervical Cancer

Keiichi Fujiwara, MD, PhD, discusses the significance of the FDA approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.

Dani Castillo, MD

Latest:

Integrating FGFR2b Detection Into Standard Treatment Pathways

Panelists discuss how integrating FGFR2b testing into routine diagnostic workflows will be essential to fully realize the benefits of targeted therapy.

Alessandro Villa, DDS, PhD, MPH

Latest:

The Importance of Oral Medicine in Cancer: Evaluation and Treatment

Alessandro Villa, DDS, PhD, MPH, discusses the importance of oral medicine in cancer treatment.

Matthias Preusser, MD

Latest:

Q&A: Final Questions on Glioblastoma and Neuroimaging

Nathalie Albert, MD, and Matthias Preusser, MD, address audience questions and share their insights on promising and anticipated advancements in neuroimaging techniques, highlighting the potential impact of these emerging strategies on the diagnosis, monitoring, and treatment of glioblastoma.

Avyakta Kallam, MBBS

Latest:

Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS Lymphoma

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.

Jacob J. Adashek, DO

Latest:

Dr. Adashek on Targeting Molecular Alterations to Treat Multiple Tumor Types

Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.